Compounds > hydrochlorothiazide

hydrochlorothiazide and rofecoxib

hydrochlorothiazide has been researched along with rofecoxib in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Alon, US; Pattaragarn, A1
Hoefsloot, L; Kasap, B; Kavukçu, S; Oğün, N; Oztürk, Y; Soylu, A; Türkmen, M1

Other Studies

5 other study(ies) available for hydrochlorothiazide and rofecoxib

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor.
    Pediatric nephrology (Berlin, Germany), 2003, Volume: 18, Issue:10

    Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diabetes Insipidus, Nephrogenic; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Infant, Newborn; Isoenzymes; Lactones; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Sodium Chloride Symporter Inhibitors; Sulfones

2003
Efficacy of COX-2 inhibitors in a case of congenital nephrogenic diabetes insipidus.
    Pediatric nephrology (Berlin, Germany), 2005, Volume: 20, Issue:12

    Topics: Amiloride; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diabetes Insipidus, Nephrogenic; Diuretics; DNA Mutational Analysis; Follow-Up Studies; Genetic Diseases, X-Linked; Humans; Hydrochlorothiazide; Infant; Lactones; Male; Receptors, Vasopressin; Sulfones; Time Factors; Treatment Outcome

2005